The price of Freeline Therapeutics Holdings plc (NASDAQ:FRLN) shares last traded on Wall Street rose 54.99% to $5.75.
Based on available information, 4 analysts follow Freeline Therapeutics Holdings plc (NASDAQ:FRLN). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $30.00 and a low of $3.00, we find $15.00. Given the previous closing price of $3.71, this indicates a potential upside of 304.31 percent. FRLN stock price is now 92.09% away from the 50-day moving average and -18.90% away from the 200-day moving average. The market capitalization of the company currently stands at $24.67M.
Among analysts, 1 rate the stock a hold while 3 rate it a buy. Brokers who have rated the stock have averaged $13.60 as their price target over the next twelve months.
There have been several recent changes in the stakes of large investors in FRLN stock. A new stake in Freeline Therapeutics Holdings plc shares was purchased by VIRTU FINANCIAL LLC during the first quarter worth $6,000.
A candlestick chart of Freeline Therapeutics Holdings plc (NASDAQ: FRLN) showed a price of $3.89 on Wednesday morning. During the past 12 months, Freeline Therapeutics Holdings plc has had a low of $2.11 and a high of $14.84. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 2.80, and a quick ratio of 2.80. The fifty day moving average price for FRLN is $3.01 and a two-hundred day moving average price translates $7.07 for the stock.
The latest earnings results from Freeline Therapeutics Holdings plc (NASDAQ: FRLN) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at $0.3, beating analysts’ expectations of -$3.1 by 3.4. This compares to -$0.63 EPS in the same period last year. The company reported revenue of $20.08 million for the quarter, compared to $28.17 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -28.71 percent.
Freeline Therapeutics Holdings plc(FRLN) Company Profile
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.
